← Patent-cliff monitor small molecule LINZESS LINACLOTIDE
Loss of exclusivity February 2034 latest FDA-listed patent expiry
Company AbbVie Inc. → See this company's full patent-cliff portfolio Drug detail Brand name LINZESS Active ingredient LINACLOTIDE Strength 145MCG Dosage form CAPSULE Route ORAL Modality Small molecule FDA approval August 2012 Marketing status RX
Listed patents Patent Expires Type 9708371*PED February 2034 — 9708371 August 2033 product 8802628*PED April 2032 — 8748573*PED April 2032 — 8802628 October 2031 product 8748573 October 2031 use U-4345 8933030*PED August 2031 — 8933030 February 2031 product 7304036*PED February 2027 — 7304036 August 2026 substance, product
Regulatory exclusivity Code Expires PED May 2029 NPP November 2028 I-921 June 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.